Results 221 to 230 of about 2,609,725 (348)

Bioactive Secondary Metabolites at the Ends of the Earth (2015-2025): Insights into Arctic and Antarctic Aquatic Sources. [PDF]

Mar Drugs
Phi KH, Heo EJ, Kwon S, Youn UJ, Lee S.
europepmc   +1 more source

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Workflows for stable cell line generation: Chemical transfection and viral transduction. [PDF]

Mol Cells
Min C, Kim J, Lee G.
europepmc   +1 more source

O-naphthoquinone isolated from Capraria biflora L. induces selective cytotoxicity in tumor cell lines

, 2015
G.G.N. de S. Wisintainer, Gustavo Scola, Sidnei Moura, Telma L. G. Lemos, Cláudia Pessoa, Manuel O. Moraes, Luciana G. S. Souza, Mariana Roesch‐Ely, João Antônio Pêgas Henriques   +8 more
openalex   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Targeting CRTC2 reverses <i>STK11</i> mutant NSCLC tumor resistance to immunotherapy. [PDF]

Proc Natl Acad Sci U S A
Robay D, Ackermann O, Laborde L, Shi X, Oreglia F, Stump R, Ciaghi S, Galli GG, Holzer L, Villemin L, Wagner J, Wu J, Lee LH, Bossen C, Mourikis TP, Gabriel M, Ruddy D, Yu H, Johannessen C, Ferretti S, Costa C.   +20 more
europepmc   +1 more source

Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens

, 2000
H. D. Menssen, Eckart Bertelmann, S. Bartelt, Robert A. Schmidt, Gabriele Pecher, K. Schramm, E. Thiel   +6 more
openalex   +2 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer. [PDF]

Cancer Immunol Immunother
Sun B, Kong M, Jiang X, Zhu L, Zhang J, Tan L, Wang C, Yuan Z, Chen S, Wang C, Jiang Y, Zhang L.   +11 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source